Literature DB >> 18201150

Oral valproic acid for epilepsy--long-term experience in therapy and side effects.

Thorsten Gerstner1, Nellie Bell, Stephan König.   

Abstract

Valproic acid (VPA) is considered to be a drug of first choice and one of the most frequently-prescribed antiepileptic drugs worldwide for the therapy of generalized and focal epilepsies, including special epileptic. It is a broad-spectrum antiepileptic drug and is usually well tolerated. Rarely, serious complications may occur in some patients, including hemorrhagic pancreatitis, coagulopathies, bone marrow suppression, VPA-induced hepatotoxicity and encephalopathy, but there is still a lack of knowledge about the incidence and occurrence of these special side effects. Additionally, the consequences for VPA therapy and indication are more or less unclear. By literature review and own data this review addresses some of the challenges of VPA therapy and its side effects, which are not unique to epilepsy in childhood.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201150     DOI: 10.1517/14656566.9.2.285

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  29 in total

Review 1.  Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.

Authors:  Na'ama A Shein; Esther Shohami
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

2.  Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors.

Authors:  Kevin Cronin; Hernando Escobar; Karoly Szekeres; Eduardo Reyes-Vargas; Alan L Rockwood; Mark C Lloyd; Julio C Delgado; George Blanck
Journal:  Hum Vaccin Immunother       Date:  2013-01-17       Impact factor: 3.452

3.  The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.

Authors:  Eli C Lewis; Lykke Blaabjerg; Joachim Størling; Sif G Ronn; Paolo Mascagni; Charles A Dinarello; Thomas Mandrup-Poulsen
Journal:  Mol Med       Date:  2010-12-22       Impact factor: 6.354

4.  Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.

Authors:  Charles A Dinarello; Gianluca Fossati; Paolo Mascagni
Journal:  Mol Med       Date:  2011-05-05       Impact factor: 6.354

5.  Valproate-induced neurodevelopmental deficits in Xenopus laevis tadpoles.

Authors:  Eric J James; Jenny Gu; Carolina M Ramirez-Vizcarrondo; Mashfiq Hasan; Torrey L S Truszkowski; Yuqi Tan; Phouangmaly M Oupravanh; Arseny S Khakhalin; Carlos D Aizenman
Journal:  J Neurosci       Date:  2015-02-18       Impact factor: 6.167

6.  Allosteric modulation of sigma-1 receptors elicits anti-seizure activities.

Authors:  Lin Guo; Yanke Chen; Rui Zhao; Guanghui Wang; Eitan Friedman; Ao Zhang; Xuechu Zhen
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

Review 7.  Anti-inflammatory Agents: Present and Future.

Authors:  Charles A Dinarello
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

8.  Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis.

Authors:  Leo A B Joosten; Flavio Leoni; Sajeda Meghji; Paolo Mascagni
Journal:  Mol Med       Date:  2011-02-11       Impact factor: 6.354

9.  Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase.

Authors:  Gang Wu; Changlong Nan; Johnathon C Rollo; Xupei Huang; Jie Tian
Journal:  J Biomed Sci       Date:  2010-03-10       Impact factor: 8.410

Review 10.  New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?

Authors:  Jacqueline A French; Deana M Gazzola
Journal:  Ther Adv Drug Saf       Date:  2011-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.